View Post

NICE approves routine use of drug combination for advanced breast cancer

In In The News by Barbara Jacoby

From: Another life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS following its approval by NICE in final draft guidance published today (23 September 2022). Palbociclib (also called Ibrance and made by Pfizer) given with fulvestrant, another type of anti-cancer treatment, is recommended for adults with a type …

View Post

NICE Approves Adjuvant Trastuzumab for HER2-positive Early Breast Cance

In Clinical Studies News by Barbara Jacoby

By: Dawn O’Shea   From: The National Institute for Health and Care Excellence (NICE) has approved trastuzumab emtansine as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy. Trastuzumab is an adjuvant …